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1. Introduction
Cancer chemotherapy is designed to kill cancer cells, with most agents inducing DNA dam‐
age. Highly conserved DNA repair machinery that process DNA damage and maintain genomic
integrity developed during the evolution of mammalian cells. Interestingly, in established
tumors, DNA repair activity is required to counteract oxidative DNA damage that is preva‐
lent within the tumor microenvironment. If the damaged DNA is successfully repaired, the cell
will survive.
In order to specifically and effectively kill cancer cells using chemotherapy that induce DNA
damage, it is important to take advantage of specific abnormalities in the DNA damage response
machinery that are present in cancer cells but not in normal cells. Such properties of cancer cells
may be targets for sensitization and lead to the development of biomarkers. Furthermore,
inhibition of a DNA damage response pathway may enhance the therapeutic effects of DNA-
damaging agents when employed in combination with these agents.
Recently, DNA repair inhibition has emerged as a promising strategy for personalized cancer
therapy. Synthetic lethality exploits inter-gene relationships where the loss of function of either
one of two related genes is nonlethal, but loss of both causes cell death. Emerging clinical data
provide compelling evidence that overexpression of DNA repair factors may have prognostic
and predictive significance in patients.
In this chapter, we will provide an overview of major DNA repair pathways and describe recent
advances in anticancer therapy with a focus on DNA repair in cancer.
2. DNA damage response
The cellular DNA damage response (DDR) involves activation of cell cycle checkpoints to
induce cell cycle arrest while repair mechanisms, transcriptional modulation, and/or apoptotic
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pathways are activated. DNA damage induced by anticancer agents triggers recruitment of
multiprotein complexes and activates a number of pathways, including ataxia telangiectasia
mutated (ATM) and ATM and Rad3-related (ATR) signaling pathways. Cell cycle checkpoint
kinases (Chk) of Chk1 and Chk2 are functionally redundant protein kinases that respond to
checkpoint signals, initiate ATM and ATR, and play a critical role in determining cellular
responses to DNA damage [1, 2]. Chk1 is mainly activated through ATR-mediated phosphor‐
ylation. Activated Chk1 phosphorylate Cdc25A, which leads to ubiquitin-and proteasome-
dependent protein degradation, and downstream to increased phosphorylation of cyclin-
dependent kinase (CDK) 2. In contrast, Chk2 is activated mainly by ATM, and activated Chk2
phosphorylates Cdc25A. Activated Chk1 and Chk2 then phosphorylates diverse downstream
effectors, which in turn are involved in cell cycle checkpoints (i.e., G1/S-phase, intra-S-phase,
and G2/M-phase checkpoints), the DNA replication checkpoint, and the mitotic spindle



















ATM, ataxia telangiectasia–mutated; ATR, ATM and Rad3–related; CHK, checkpoint kinase.
Figure 1. DNA-damage response signaling pathways
Consequently, through regulating the activity of CDKs, the progression from one cell cycle
phase to another is delayed. The resulting cell cycle arrest allows time for repair, thereby
preventing genome duplication or cell division in the presence of damaged DNA.
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3. DNA repair pathways
DNA repair pathways in mammalian cells maintain genomic integrity. Depending on the type
of DNA damage, cells invoke specific DNA repair pathways in order to restore genetic
information.
Minor changes to DNA such as oxidized or alkylated bases, small base adducts and single-
strand breaks (SSBs) are restored by the base excision repair (BER) pathway [3]. Poly(adenosine
diphosphate ribose) (PAR) polymerase (PARP) is important in this process. Upon detection of
SSBs, PARP covalently transfers PAR chains to itself and to acceptor proteins in the vicinity of
the lesion, thereby facilitating the repair of SSBs. More complex, DNA helix-distorting base
lesions, such as those induced by UV light, are repaired by nucleotide excision repair (NER)
[4]. Another kind of damage disturbing the helical structure of DNA is represented by base
mismatches. Mismatch repair factors recognize and process misincorporated nucleotides as
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BER, base excision repair; HRR, homologous recombination repair; ICL, inter-strand crosslink;
MMR, mismatch repair; MMC, mytomycin C; NER, nucleotide excision repair;
NHEJ, non-homologous end joining; SSBR, single-strand break repair; Topo, topoisomerase.
Figure 2. DNA repair pathways and chemotherapeutic agents
Covalent links between the two strands of the double helix represent a type of DNA damage
referred to as interstrand crosslinks (ICLs). ICLs represent the most deleterious lesions
produced by chemotherapeutic agents such as mitomycin C (MMC), cisplatin and cyclophos‐
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phamide. ICL repair is complex and involves the collaboration of several repair pathways,
namely Fanconi anaemia, NER, translesion synthesis (TLS) and homologous recombination
(HR) [6].
So far, four mechanistically distinct DNA double-strand break (DSB) repair mechanisms in
mammalian cells have been described: non-homologous end joining (NHEJ), alternative NHEJ,
single-strand annealing and HR [7]. NHEJ and HR represent the two major DSB repair
pathways, with NHEJ operating throughout the cell cycle and HR being the most active during
S-phase [8].
4. Cancer therapies targeting DNA repair mechanism
Alterations in expression of DNA repair may influence cancer biology and aggressive pheno‐
types. Clinical evidence supports the hypothesis that overexpression of DNA repair factors
may have prognostic and predictive significance in patients [9]. Furthermore, highly prolifer‐
ative cancer cells are hypersensitive to DNA damage because the S-phase is the most vulner‐
able period of the cell cycle. Therefore, DDR pathways make an ideal target for therapeutic
intervention.
Dysfunction of one DNA repair pathway may be compensated by the function of another
compensatory DDR pathway, which may be increased and contribute to resistance to DNA-
damaging chemotherapy. So, inhibition of the pathway in combination with DNA damage
agents will selectively kill cancer cells. These hypotheses are currently being tested in the
laboratory and are being translated into clinical studies.
5. Direct repair
The simplest form of DNA repair is direct reversal of the lesion. Direct reversal of the oxidative
lesion O6-methylguanine is carried out by the suicide enzyme methylguanine methyltrans‐
ferase (MGMT) via an active site Cys145 that acts as a methyl recipient, followed by rapid
ubiquitin-induced degradation. MGMT expression is one of several factors governing the
response to alkylating chemotherapy agents [10, 11].
MGMT demethylates O6-methylguanine lesions, which are formed as a result of erroneous
methylation by S-adenosylmethionine (SAM) and other alkylations at the O6 position of
guanine that are induced by dietary nitrosamines or chemotherapy agents such as temozolo‐
mide (TMZ), dacarbazine (DTIC) and nitrosoureas [12, 13]. The higher levels of MGMT that
are frequently observed in tumor tissue compared with normal tissue suggest that its depletion
with pseudo-substrates that resemble O6-methylguanine might be a viable strategy to sensitize
tumor cells to O6 alkylating agents. However, these pseudo-substrates have shown only
marginal clinical benefit [14, 15].
A more promising approach may be the exploitation of reduced MGMT activity owing to
epigenetic silencing in some cancers [16]. MGMT promoter methylation correlated with
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sensitivity to BCNU in patients with astrocytomas and also correlated with sensitivity to TMZ
plus radiotherapy in patients with gliomas [17]. Therefore, MGMT promoter methylation
could be useful for stratifying patients for TMZ treatment.
6. Base excision repair
BER is responsible for detection and repair of damage caused by a number of mechanisms
including alkylation, oxidation by reactive oxygen species (ROS), SSBs and base deamination.
BER repairs DNA damage that is therapeutically induced by ionizing radiation, DNA-
methylating agents, topoisomerase I poisons such as camptothecin, irinotecan and topotecan
[18]. Single-strand break repair (SSBR) and BER are often assumed to be synonymous because
they involve the same components and are similar after the initial recognition step. The main
components of the pathway are glycosylases, endonucleases, DNA polymerases and DNA
ligases, with PARP1 and PARP2 facilitating the process. Damaged bases are first removed by
BER glycosylases to form apurinic or apyrimidinic (AP) sites. BER endonucleases then generate
an SSB, which along with directly induced SSBs and those generated by topoisomerase (topo)
I poisons [19, 20], are the substrates for SSBR. On detecting SSBs, PARP1 rapidly becomes
bound and poly(ADP-ribosyl)ated, protecting the nick ends from undesirable recombination
and allowing the recruitment of the molecular scaffold protein X-ray repair cross-comple‐
menting protein (XRCC) 1 for ongoing repair [21].
The BER pathway is an attractive target for the modulation of chemosensitivity. Early
inhibitors of DNA polymerase-β (Pol β), flap endonuclease 1 (FEN1), ligase 1 and ligase 3
enhance sensitivity to ionizing radiation and TMZ. However, the most advanced drugs that
target this pathway are AP endonuclease 1 (APE1) inhibitors and PARP-inhibitors (PARP-i,
described later). Both APE1 and PARP expression and/or activity are generally higher in
tumors [9, 22, 23].
There are two classes of APE1 inhibitor: methoxyamine, which binds the AP site in DNA, and
inhibitors of APE1 endonuclease activity. Preclinically, methoxyamine potentiates the
cytotoxicity of TMZ [24] and pemetrexed. In a phase I trial of methoxyamine, responses were
seen in combination with pemetrexed, and there is an ongoing study with TMZ. Lucanthone,
a topo II inhibitor, also inhibits APE1 endonuclease activity and potentiates the cytotoxicity of
DNA-methylating agents in breast cancer cells [25]. Novel, more specific, APE1 endonuclease
inhibitors increased the persistence of AP sites in vitro and increased the cytotoxicity of
alkylating agents [26]. The synthetic lethality relationship between HR and APE1 was con‐
firmed by the observed cytotoxicity following ATM inhibitor exposure in APE1−/− cells [27].
7. Nucleotide excision repair
NER recognizes and repairs base lesions associated with distortion of the DNA helical
structure, including UV-induced photoproducts not eliminated by direct repair, and an array
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of bulky adducts induced by various exogenous chemical agents. NER removes helix-
distorting adducts on DNA and contributes to the repair of intrastrand and ICLs; the xero‐
derma pigmentosum (XP) proteins and excision repair cross-complementation group 1
(ERCC1) also have crucial roles in both the NER and ICL repair pathways [28]. Deficiency in
NER confers sensitivity to platinum agent therapy, which reflects a reduced capacity to repair
ICLs [29, 30]. There are currently no small molecule inhibitors of NER, although cyclosporine
and cetuximab might down-regulate XPG and ERCC1–XPF expression, respectively. Recent
evidence suggests that the efficacy of PARP-i–topo I poison combinations may be most
effective in tumors that lack ERCC1–XPF, which are involved in the NER pathway [31].
8. Mismatch repair
Mismatch repair (MMR) recognizes and repairs errors introduced during replication. MMR
also recognizes and repairs insertion/deletion loops (IDLs), particularly within microsatellite
DNA. Hence, “microsatellite instability” (MSI) is recognized as a hallmark of MMR failure [32,
33]. If MSI manifests within tumor suppressor genes, it can produce frameshift mutations that
contribute to carcinogenesis in colorectal, endometrial, ovarian, and gastric cancers [34].
Defective MMR increases mutation rates up to 1,000-fold, results in MSI, and is associated with
cancer development [35].
Several DDR genes have microsatellites and could be mutated in MSI-high cancer, potentially
conferring sensitivity to some DNA-damaging agents [36, 37]. However, defects in MMR cause
tolerance to TMZ, platinum agents and some nucleoside analogues, which leads to drug
resistance [38, 39]. Some researchers have focused on attempts to reactivate epigenetically
silenced MLH1. However, after promising preclinical data that demonstrated chemosensiti‐
zation [40], clinical trials have shown adverse reactions.
9. Homologous Recombination Repair
HR repair (HRR) is crucial for the maintenance of genomic stability, and is the predominant
mechanism for DSB. HRR pathway for DSB repair is a highly complex process that involves
multiple proteins, and occurs during the S and G2 phases of the cell cycle [41]. Many tumor
suppressors participate in this pathway, including BRCA1, BRCA2 and ATM. As hetero‐
zygosity at a BRCA allele is associated with effective HR, DSB accumulation induced by PARP-
inhibition specifically occurs only in tumor cells with acquired BRCA−/− homozygosity [42,
43]. Reasons for “BRCAness” are inactivation of BRCA1 or BRCA2 function caused by aberrant
epigenetic or posttranslational modifications, and a wider range of mutations in other genes
resulting in defective DSB signaling and HRR. Tumors with HRR defects are highly sensitive
to crosslinking agents such as cisplatin, carboplatin and nitrosoureas, and DSBs that are
induced by ionizing radiation and topo I poisons.
The high frequency of HRR defects in tumors may underlie the efficacy of cytotoxic therapy
and provide a rationale for the use of inhibitors of HRR in the sensitization of tumors with
Advances in DNA Repair364
functional HRR to conventional chemotherapy. Recent evidence suggests that PARP-i induces
single agent cytotoxicity in cells with reduced expression of ATM, the checkpoint activator
that is activated by DSBs [27, 44]. There are few HRR inhibitors, but mirin is an inhibitor of
MRE11 endonuclease activity and thus inhibits HRR function [45]. Germline mutations in the
HR protein RAD51D confer susceptibility to ovarian cancer and may be a target for PARP-i in
a small subset of women [46]. Other prototype RAD51 inhibitors have been identified but the
most common way to target HRR is by inhibition of the ATM–ChK2 or ATR–Chk1 pathways.
Hyperactive growth factor signaling and oncogene-induced replicative stress increase DNA
breakage that activates the ATR–Chk1 pathway, and some examples of synthetic lethality of
checkpoint or DNA repair inhibitors in cells harbouring activated oncogenes have been shown.
ATR knockdown was synthetically lethal in cells that were transformed with mutant KRAS
[47], and inhibition of Chk1 and Chk2 significantly delayed disease progression of transplant‐
ed MYC-overexpressing lymphoma cells in vivo [48].
10. Non-homologous end joining
NHEJ is thought to be the major pathway for DSB repair. Damage recognition in NHEJ is
performed by the Ku70/Ku80 heterodimer, which binds to the DSB ends with high affinity,
possibly tethering the broken ends together. Ku binding recruits and activates the DNA-
dependent protein kinase catalytic subunit (DNA-PKcs), forming the DNA-PK complex that
phosphorylates other repair proteins including XRCC4-like factor (XLF), Werner syndrome
helicase, DNA ligase IV and XRCC4.
DNA-PKcs is a member of the PI3K-related protein kinase family of enzymes that also includes
ATM, ATR and mammalian target of rapamycin (mTOR). PI3K inhibitors, such as wortmannin
and LY294002, also inhibit DNA-PKcs, and in proof-of-concept studies, these drugs hindered
DSB rejoining and enhanced the cytotoxicity of DSB-inducing agents [49, 50]. More potent and
specific DNA-PKcs inhibitors have been developed [51, 52] that substantially slow DSB repair
and increase the cytotoxicity and antitumor activity of IR, radiomimetics and topo II poisons
in cells and xenografts [53, 54]. However, none of these agents have reached the clinical testing
stage.
11. Translesion synthesis
If damaged DNA bases or adducts are not repaired, they may stall replication forks, which
could contribute to genomic instability [55]. Several DNA polymerases can synthesize DNA
past DNA lesions. Such TLS contributes to survival. However, errors can occur because these
polymerases have no proofreading function and therefore, TLS should be considered a DNA
damage tolerance mechanism rather than a DNA repair mechanism. Defects in TLS polymer‐
ases contribute to carcinogenesis but also confer sensitivity to DNA-damaging agents, and
inhibitors of these polymerases are starting to emerge [56, 57].
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12. Synthetic lethal strategies
Perhaps the most promising prospect for cancer treatment is the exploitation of dysregulated
DDR by the synthetic lethality approach. Synthetic lethality exploits inter-gene relationships
where the loss of function of either one of two related genes is nonlethal, but loss of both causes
cell death. Loss of some elements of one DNA repair pathway may be compensated by the
increased activity of other elements or pathways. The discovery of the synthetic lethality
relationship between PARP1 and BRCA suggests that other tumor-specific defects in DSB
repair factors may be therapeutically targeted by PARP inhibition.
The best characterized synthetic lethality relationship is between BRCA mutation and PARP1
inhibition [58-60]. BRCA1 and-2 have long been known as tumor suppressors, and their
inherited mutation increases susceptibility to breast and ovarian tumors [61]. Both BRCA gene
products have a role in the HRR pathway [62]. In BRCA-deficient cells, loss of effective HR
leads to DSB persistence and cell death. However, resistance to PARP-i can develop owing to
secondary mutations in BRCA1 or BRCA2 that restore their function [63, 64]. In addition, even
in BRCA-mutant cells, HRR function and PARP-i resistance can be restored if 53BP1 or DNA-
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HR, homologous recombination; PARP, poly-adenosine-diphosphate-ribose (PAR) polymerase.
Figure 3. Tumor selective synthetic lethality
Beyond BRCA1 and BRCA2, their joint interaction partner PALB2 is emerging as a breast
cancer susceptibility gene, thus providing another opportunity for PARP-i-based therapies
[67]. NVP-BEZ235, a recognized dual PI3K/mTOR inhibitor, was also reported to efficiently
Advances in DNA Repair366
block ATM, ATR and DNA-PK activity. Furthermore, NVP-BEZ235 was found to act as a radio-
and chemosensitizer in various cancer cell lines [68, 69] and is currently being tested as a single
agent in various phase I/II clinical trials [70, 71].
Synthetic lethality of components of the cell cycle checkpoint machinery could be exploited in
cancers harbouring activated oncogenes, since oncogene-induced replication stress activates
the ATR-Chk1 signaling pathway. Importantly, more than 50% of human tumors are defective
in p53 tumor suppressor function and cell cycle checkpoint inhibitors have been demonstrated
to sensitize p53-deficient cancer cells to various anticancer agents in clinical use [72]. The two
transducer kinases Chk1 and Chk2 are downstream of ATM and ATR, and several inhibitors
of transducer kinases have emerged in recent years. Recently, three novel Chk1 inhibitors,
GDC-0425, SCH900776 and LY-2606368, have entered phase I clinical trials either as single
agents or in combination with gemcitabine, a nucleoside analogue [73]. Another promising
drug that interferes with checkpoint activation is the WEE1 tyrosine kinase inhibitor MK-1775
[74]. MK-1775 is already under investigation in a phase II trial combined with carboplatin in
order to assess the benefit for patients with p53-mutated epithelial ovarian cancer. Several
agents targeting CDC25 phosphatases that represent key molecules in checkpoint regulation
have also been developed [75, 76].
SSBR factors other than PARP1 are potential synthetic lethality partners in DSB repair loss,
which is supported by the observed cytotoxicity induced by inhibitors of ATM or DNA-
PKcs following knockdown of the BER protein XRCC1 [77]. Recent evidence suggests that
relationships between BER and non-HR DNA repair pathways may have potential synthetic
lethality.  The ATR inhibitor  NU6027 was  also  more  profoundly cytotoxic  to  BER-defec‐
tive cells and in BER-functional cells treated with a PARP-i, reflecting the complementari‐
ty of HRR and BER [78].
Phosphatase and tensin homolog (PTEN) is a negative regulator of the anti-apoptotic
PI3K/Akt/mTOR pathway. PTEN has recently been implicated in the maintenance of genomic
integrity [79-83]. In the nucleus, PTEN promotes chromosome stability and DNA repair. PTEN
loss-of-function could be an effective target for treatment strategies. Since PTEN deficiency
causes a defect in HR, cells rely on PARP for the repair of DSBs. PTEN deficiency therefore
sensitizes cancer cells to PARP inhibition [84-86]. Mendes-Pereira et al. [84] tested for synthetic
lethality in HCT116 colorectal tumor cells transfected with a PTEN-mutant cDNA clone.
Homozygosity for PTEN mutation was associated with a 20-fold increase in sensitivity to
PARP-i in vitro and in vivo. Ectopic expression of RAD51 in a PTEN-deficient cell line
overcame PARP-i sensitivity, supporting the proposed link between PTEN mutation and
reduced RAD51 expression. Similar results were demonstrated in uterine endometrial
carcinoma [85]. In primary PTEN−/− mouse astrocytes, reduced transcription of the RAD51
paralogs was associated with sensitivity to PARP inhibition [86], while PTEN disruption in
colorectal cancer cells resulted in reduced MRE11 accumulation at DSBs that is also associated
with PARP-i sensitivity [87]. Prostate cancers exhibiting PTEN loss often harbor a genetic
rearrangement leading to TMPRSS22-ERG fusion. The TMPRSS22-ERG protein product
promotes the formation of DNA DSBs and interacts with PARP, thus sensitizing cells to PARP
inhibition [88, 89]. In lung cancer cells, PTEN deficiency potentiated the synergistic effect of
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olaparib and cisplatin combination treatment [90], while rucaparib sensitized PTEN-deficient
prostate cancer cells to ionizing radiation [91]. In melanoma cells, PTEN loss may contribute
to BRAF and APE1 inhibition [92, 93]. Retrospective analysis of genetic alterations and PTEN
status in tumors taken from patients who are participating in an ongoing clinical trial will
provide information for the development of synthetic lethal treatment involving PTEN [94].
Mutations of the von Hippel–Lindau (VHL) tumor suppressor gene occur in the majority of
sporadic renal cell carcinomas (RCC). The lack of VHL function in cells results in decreased
repair capacity [95]. For example, the suppressor of cytokine signaling 1 (SOCS1) promotes
nuclear redistribution and K63 ubiquitylation of VHL in response to DSBs. Loss of VHL
function or VHL mutation that compromises K63 ubiquitylation attenuates the DDR, result‐
ing in decreased HRR and persistence of DSBs [96]. Furthermore, loss of VHL function is as‐
sociated with stabilization of hypoxia-inducible factor α (HIFα). The exposure of cells to
hypoxia markedly enhances genetic instability caused by exogenous genotoxins, and HIF
activation decreased NER [97]. Recently, synthetic lethal (SL) partner of VHL was identified
from a screening of large volumes of cancer genomic data using a small interfering RNA
screen. The VHL-deficient cells are significantly more sensitive to the knockdown of the pre‐
dicted VHL-SL partners [98]. DNA repair pathway abnormalities involving VHL dysfunc‐
tion might be therapeutic targets.
Many strategies based on the concept of synthetic lethality have so far only been investigated
in preclinical settings.
13. PARP inhibitor
A number of potential PARP-i have been identified. In xenograft and in vitro models, PARP-
i have been demonstrated to potentiate the action of a wide variety of damaging agents
including platinums, the alkylating agents TMZ and cyclophosphamide, the nucleoside
analogue gemcitabine, the topo inhibitor irinotecan, and ionizing radiation [90]. Furthermore,
preclinical studies also suggested the potential use of PARP-i in sporadic cancers that share
phenotypical features with cancers arising from hereditary BRCA mutations, a phenomenon
that is referred to as “BRCAness” [91]. Many additional phase I and II trials are currently
underway, examining the combination with a variety of agents including carboplatin, 5-
fluorouracil and oxaliplatin, cisplatin and paclitaxel, topotecan, gemcitabine, and radiotherapy
[92]. For example, rucaparib has been evaluated in phase I and II studies in combination with
TMZ for malignant melanoma, demonstrating successful PARP inhibition at the tissue level
and probable anticancer activity, but significant myelosuppression caused dose-limiting
toxicity [93].
An initial phase I study of olaparib in a cohort enriched for BRCA1/2 mutation carriers
demonstrated evidence of in vivo anti-PARP activity and evidence of response in 40% of BRCA
carriers [60]. Phase II trials of olaparib for breast or ovarian cancer associated with BRCA1/2
mutations were favorable, suggesting antitumor efficacy [94, 95]. Good responses were also
seen in patients with BRCA-associated breast and ovarian cancers, and even in unselected
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patients with high-grade serous ovarian cancer [96, 97]. However, olaparib did not progress
to a phase III trial for hereditary BRCA mutation-associated breast cancer due to economic
concerns [98].
Iniparib has been evaluated in a phase II study of metastatic triple-negative breast cancer
treatment in combination with gemcitabine and carboplatin. A significantly improved median
overall survival was demonstrated compared with gemcitabine and carboplatin, without
increased toxicity. However, a phase III trial failed to meet co-primary endpoints of overall
and progression-free survival improvement, and after further disappointing results in a phase
III non-small cell lung cancer trial, iniparib has been suspended from further development [99].
A good safety profile was also observed with veliparib in combination with TMZ. This was
associated with early positive results in metastatic colorectal and BRCA-deficient breast
cancers, although the combination was associated with poor response and no progression-free
or overall survival improvement in advanced melanoma. Likewise, phase II investigation of
rucaparib in BRCA1/2-mutated breast or ovarian cancer demonstrated PARP activity inhibi‐
tion and evidence of a tumor response. The oral PARP1/2 inhibitor niraparib has also been
evaluated at phase I and was shown to possess an acceptable safety profile and probable
antitumor activity. Other PARP-i including orally bioavailable agents are currently being
tested in clinical trials [100].
Clinical trials of PARP-i have generally been disappointing owing to toxicity, which may be
due to use of a dose of PARP-i that was established as safe when used as a single agent. In
general, preclinical data indicated that the MTD of single agent PARP-i was much higher than
MTD of PARP-i when combined with another cytotoxic agent such as TMZ [101, 102]. This is
because almost total inhibition of PARP-i is needed to render endogenous DNA damage
cytotoxic, but this level of inhibition is not necessary to render the additional burden of
deliberately introduced DNA damage cytotoxic, both in the tumor and in proliferating normal
tissues. In addition, secondary BRCA2 mutations have been identified, which restore the full-
length protein, thereby re-establishing BRCA2 functions and conferring PARP-i resistance
[103]. A major challenge of using PARP-i is the acquired resistance of initially PARP-i-sensitive
cancer cells due, for example, to the loss of p53-binding protein-1 (53BP1) or to overexpression
of multidrug-resistance efflux transporters [104, 105]. The data described above suggest that
the clinical utility of PARP-i in combination with chemotherapy may be limited in tumors in
view of its narrow therapeutic index.
14. Predictive biomarkers
Relevant biomarker assays should predict the functionality of DNA repair pathways, rather
than just providing information about mutations or expression levels of proteins involved in
the DNA repair pathway. Furthermore, such detailed molecular profiling of cancer versus
normal tissue from a given patient is critical to maximize the potential of personalized cancer
drugs in terms of both therapeutic success and cost-effectiveness.
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A general marker of DNA damage is the phosphorylation of histone H2AX by ATM, ATR and
DNA-PK. γH2AX foci, formed at sites of DSBs, or increased levels of γH2AX, may be measured
by immunofluorescence microscopy, flow cytometry or immunoblotting and used to detect
DNA damage [106]. The increase and/or persistence of γH2AX can be used to demonstrate the
inhibition of PARP, DNA-PK, ATR and Chk1. To directly measure the effect of a molecularly
targeted agent, immunological methods may be used to detect the product. For example,
activation of DNA-PK and ATM in response to DNA damage can be determined by measuring
their autophosphorylation with phospho-specific antibodies, and PARP activity may be
measured by immunodetection of the ADP-ribose polymer product, to guide PARP-i clinical
trials [60, 107-109]. In multiple clinical trials, PARP activity in peripheral mononuclear blood
cells has been used as a marker of effective inhibition [110, 111].
An alternative approach is to assess HRR function in fresh viable tumor material by measuring
the number of RAD51 foci following ex vivo DNA damage induction [112-114]. In the ovarian
cancer study, this was further analyzed in BRCA2-mutated pancreatic cancer cell clones to
predict RAD51 foci formation as a marker of HR, and to examine for sensitivity to PARP
inhibition.
When inactivation of a single gene has been identified as a crucial determinant of sensitivity,
it may then be used to select patients for the appropriate therapy. For example, low levels of
the NER endonuclease ERCC1 correlate with cisplatin sensitivity in several cancers [30, 115,
116]. Several studies report methods to identify tumors with non-germline HRR defects: gene
expression profiling, methylation-specific arrays, immunohistochemistry analysis of tissue
microarrays and copy number aberrations by array comparative genomic hybridization.
[117-121]
Immunohistochemistry analysis of formalin-fixed, paraffin-embedded samples may be a
useful tool for identifying DDR defects in order to stratify patients. To measure the effect of
an agent that directly causes DNA DSBs in all phases of the cell cycle, patient-derived
lymphocytes can be used [122]. Owing to the invasive procedures that are needed to obtain
tumor material, except in the case of hematological malignancies, circulating tumor cells offer
the best hope of routinely obtaining suitable material [123].
15. Conclusion
DNA repair mechanisms play an essential role in promoting genomic stability. On the other
hand, impaired DNA repair capacity in cancer cells may result in a favorable response to
chemotherapy. Many conventional therapeutic regimens that effectively kill cancer cells are
based on DNA damage. However, most chemotherapeutic regimens cause severe side effects
that limit their therapeutic potential. Inhibition of DNA repair is a new paradigm in cancer
therapy, and there is heightened interest in the therapeutic potential of these inhibitors that
selectively target tumors with minimal host toxicity.
The synthetic lethal approaches targeting the individual genetic profile of the tumors are under
clinical development. The molecular characterization of tumors and reliable biomarkers are
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needed for effective personalized therapy. Further research is necessary in order to determine
the most appropriate treatment for patients.
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